Financial Performance - The company's operating revenue for Q1 2023 was ¥246,445,272.15, representing a decrease of 15.19% compared to the same period last year[3] - The net profit attributable to shareholders was ¥26,310,732.19, down by 4.43% year-on-year[3] - The basic earnings per share for the period was ¥0.20, reflecting a decline of 4.76% compared to the previous year[3] - Total operating revenue for Q1 2023 was CNY 246,445,272.15, a decrease of 15.2% compared to CNY 290,586,279.28 in Q1 2022[13] - Net profit for Q1 2023 was CNY 25,635,740.84, a decline of 4.2% from CNY 26,763,211.11 in Q1 2022[14] - The net profit attributable to the parent company for Q1 2023 was CNY 26,310,732.19, a decrease of 4.4% compared to CNY 27,529,731.11 in Q1 2022[15] - The total operating revenue from sales of goods and services in Q1 2023 was CNY 192,568,787.82, a decline of 9.4% from CNY 212,565,168.83 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,222,032,915.04, an increase of 3.92% from the end of the previous year[4] - Total assets as of March 31, 2023, were CNY 2,222,032,915.04, an increase from CNY 2,138,160,094.23 at the end of 2022, marking a growth of 3.9%[12] - Total liabilities increased to CNY 701,845,128.22 from CNY 655,756,145.87 at the end of 2022, representing a rise of 7%[12] - Non-current assets totaled CNY 1,695,214,247.90, up from CNY 1,667,874,751.61 at the end of 2022, indicating a growth of 1.6%[11] Cash Flow - The net cash flow from operating activities was negative at -¥12,432,495.15, indicating a significant decline in cash generation[3] - The net cash flow from operating activities for Q1 2023 was negative at CNY -12,432,495.15, compared to a positive CNY 9,037,458.54 in Q1 2022[18] - The company incurred a total cash outflow from operating activities of CNY 207,996,715.51 in Q1 2023, slightly higher than CNY 205,447,864.92 in Q1 2022[18] - The net cash outflow from investing activities for Q1 2023 was CNY -31,422,829.04, compared to CNY -8,785,815.73 in Q1 2022[19] - The company reported cash inflows from financing activities of CNY 125,600,000.00 in Q1 2023, an increase from CNY 115,370,000.00 in Q1 2022[19] - The company reported a net cash inflow from financing activities of CNY 72,635,872.05 in Q1 2023, compared to CNY 66,972,377.01 in Q1 2022[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,087[6] - The top shareholder, Wu Renrong, holds 13.67% of the shares, with 10,890,000 shares pledged[7] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 214,807,670.05, down 16.6% from CNY 257,641,185.97 in Q1 2022[14] - The company reported R&D expenses of CNY 12,944,144.72 for Q1 2023, an increase of 19.3% compared to CNY 10,847,878.76 in Q1 2022[14] Inventory and Receivables - Cash and cash equivalents increased to CNY 128,322,164.94 as of March 31, 2023, compared to CNY 99,827,619.02 at the end of 2022, representing a growth of 28.5%[11] - Accounts receivable rose to CNY 152,574,670.50, slightly up from CNY 151,137,005.14 at the end of 2022, indicating a 1% increase[11] - Inventory increased to CNY 185,884,308.49, up from CNY 165,129,389.22 at the end of 2022, reflecting a growth of 12.5%[11] Borrowings - Long-term borrowings increased by 42.54%, attributed to new bank loans during the reporting period[5] Miscellaneous - The weighted average return on equity decreased by 0.21 percentage points to 1.76%[3] - The company did not report any net profit from the merged entity in the current or previous period[16]

Financial Performance - The company's operating revenue for Q3 2022 was ¥262,865,410.62, a decrease of 5.92% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2022 was ¥17,789,152.14, down 34.94% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,270,113.68, a decline of 38.46% compared to the previous year[3]. - The basic earnings per share for Q3 2022 was ¥0.13, reflecting a decrease of 38.10% year-over-year[4]. - The net profit for Q3 2022 was CNY 77,248,178.32, a decrease of 7.4% compared to CNY 83,384,566.77 in Q3 2021[18]. - The operating profit for Q3 2022 was CNY 88,142,528.77, down 21.9% from CNY 112,796,265.16 in Q3 2021[18]. - The total comprehensive income for Q3 2022 was CNY 77,248,178.32, down from CNY 83,384,566.77 in Q3 2021[19]. - Basic and diluted earnings per share for Q3 2022 were CNY 0.59, a decrease from CNY 0.64 in Q3 2021[19]. Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥850,975,692.57, an increase of 11.4% compared to ¥764,195,246.66 in the same period of 2021[17]. - Total operating costs for the first three quarters of 2022 were ¥764,101,966.80, up from ¥652,384,213.26 in 2021, reflecting a year-on-year increase of 17.1%[17]. Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,081,052,946.01, representing a 13.01% increase from the end of the previous year[4]. - The total assets of the company reached ¥2,081,052,946.01, up from ¥1,841,426,562.78 at the end of 2021, reflecting a growth of 13.0%[15]. - The company reported a significant increase in total liabilities to ¥618,779,501.63 as of September 30, 2022, compared to ¥456,012,175.77 at the end of 2021, representing a rise of 35.6%[14]. - The company’s total liabilities increased, with a significant rise in borrowings to CNY 360,870,000.00 in Q3 2022 from CNY 170,559,040.00 in Q3 2021[23]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥40,452,488.32[3]. - The cash flow from operating activities for the first three quarters of 2022 was CNY 40,452,488.32, a significant improvement from a negative cash flow of CNY -78,272,989.21 in the same period of 2021[22]. - The company reported a net cash outflow from investing activities of CNY -175,558,816.01 for the first three quarters of 2022, compared to CNY -20,337,564.19 in the same period of 2021[22]. - The cash and cash equivalents at the end of Q3 2022 were CNY 65,576,292.39, down from CNY 90,783,659.51 at the end of Q3 2021[23]. - The company's cash and cash equivalents as of September 30, 2022, were ¥65,576,292.39, slightly down from ¥66,263,015.19 at the end of 2021[12]. Shareholder Information - The top ten shareholders collectively hold 70.77% of the company's shares, with the largest shareholder holding 13.67%[9]. Expenses - The company reported a significant increase in management expenses, contributing to the decline in net profit[6]. - Research and development expenses for the first three quarters of 2022 were ¥36,992,312.72, slightly up from ¥34,926,014.04 in 2021, indicating a focus on innovation[17]. Government Support - The company received government subsidies amounting to ¥2,207,000.00 during the reporting period[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥148,418,923.32 as of September 30, 2022, compared to ¥120,214,744.95 at the end of 2021, representing a growth of 23.4%[12]. - Inventory levels rose to ¥170,594,791.16, up from ¥142,442,042.74 in 2021, indicating a year-on-year increase of 19.8%[13]. Borrowings - Short-term borrowings surged to ¥328,383,358.80 as of September 30, 2022, compared to ¥171,193,229.29 at the end of 2021, marking an increase of 91.9%[14].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 588,110,281.95, representing a 21.31% increase compared to RMB 484,789,805.14 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was RMB 60,762,416.76, which is a 7.55% increase from RMB 56,498,039.97 in the previous year[18]. - The net cash flow from operating activities was RMB 9,437,590.82, a significant improvement from a negative cash flow of RMB -56,032,897.92 in the same period last year, marking a 116.84% change[18]. - The total assets at the end of the reporting period were RMB 2,032,084,113.47, reflecting a 10.35% increase from RMB 1,841,426,562.78 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased to RMB 1,419,147,128.45, a 2.64% rise from RMB 1,382,705,623.96 at the end of the previous year[18]. - The basic earnings per share for the first half of 2022 was RMB 0.45, up 4.65% from RMB 0.43 in the same period last year[19]. - The weighted average return on net assets was 4.30%, slightly up from 4.28% in the previous year, indicating a marginal improvement[20]. Revenue and Sales Growth - Sales volume of synthetic lubricating base oil increased by 16.45% compared to the same period last year, with sales revenue growing by 16.22%[32]. - The sales volume of pharmaceutical excipients grew by 37.74% year-on-year, with sales revenue increasing by 32.13%[33]. - The company achieved a revenue of 588.11 million yuan in the first half of 2022, representing a year-on-year growth of 21.31%[31]. Research and Development - Research and development expenses rose by 20.63% to approximately ¥24.46 million, reflecting the company's commitment to innovation and increased investment in R&D[38]. - The company established a new application development center and a technology transformation platform of 1,600 square meters to enhance its R&D capabilities[36]. - The company has 16 ongoing projects in R&D, with 6 new projects initiated and 5 new products registered with the CDE[36]. Market and Industry Trends - The pharmaceutical industry is experiencing a shift towards domestic excipients due to rising prices and supply shortages of raw materials, leading to a reshaping of the industry[33]. - The company is focusing on expanding its market presence in response to the demand for COVID-19 related pharmaceutical excipients[33]. - The company is actively participating in the development of low-carbon emission technologies in response to national carbon neutrality goals, which presents new opportunities for synthetic lubricating base oil innovation[28]. Financial Position and Assets - The total liabilities rose to CNY 611,184,134.65 from CNY 456,012,175.77, which is an increase of approximately 34.0%[116]. - Total current assets increased to CNY 517,008,123.30 from CNY 464,691,328.94, representing a growth of approximately 11.5%[114]. - Cash and cash equivalents rose significantly to CNY 133,205,087.81, up from CNY 66,263,015.19, marking an increase of about 100.7%[114]. Risks and Challenges - The company has outlined potential risks in its management discussion, emphasizing the importance of investor awareness regarding future plans and strategies[7]. - The company faces risks related to product and technology development, particularly in meeting safety and regulatory standards for pharmaceutical excipients[47]. - Fluctuations in the prices of key raw materials, such as ethylene oxide and propylene oxide, could impact production costs and overall financial performance[48]. Shareholder and Governance - The company has not proposed any profit distribution or capital reserve transfer for the half-year period[53]. - The controlling shareholders committed to a 36-month lock-up period for their shares post-IPO, with an automatic extension of 6 months if the stock price falls below the issue price for 20 consecutive trading days within the first 6 months[67]. - The company has established strict compliance with relevant laws and regulations regarding shareholding and transfer[75]. Environmental and Compliance - The company has established an environmental management system certified by ISO 14001, ensuring compliance with local environmental standards[63]. - The company's subsidiary, Weir Bio-Tech, is classified as a key pollutant discharge unit, with no exceedance of pollutant discharge limits reported during the reporting period[57]. - Weir Bio-Tech has implemented various pollution control facilities, with treatment capacities ranging from 1,000 m³/h to 30,000 m³/h, all operating normally[58][59].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 290,586,279.28, representing a year-on-year increase of 27.77%[4] - The net profit attributable to shareholders for the same period was CNY 27,529,731.11, reflecting a growth of 5.04% compared to the previous year[4] - Total operating revenue for Q1 2022 was CNY 290,586,279.28, an increase of 27.8% compared to CNY 227,430,578.90 in Q1 2021[16] - Net profit for Q1 2022 was CNY 26,763,211.11, slightly up from CNY 26,209,240.14 in Q1 2021, reflecting a growth of 2.1%[17] - The net profit attributable to the parent company for Q1 2022 was CNY 27,529,731.11, an increase from CNY 26,209,240.14 in Q1 2021, representing a growth of approximately 5%[18] - The company reported a total comprehensive income of CNY 26,763,211.11 for Q1 2022, compared to CNY 26,209,240.14 in Q1 2021, indicating a growth of approximately 2.1%[18] Earnings and Shareholder Returns - The basic earnings per share for Q1 2022 was CNY 0.21, up by 5.00% year-on-year[4] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.21, compared to CNY 0.20 in the same period last year, indicating a 5% increase[19] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 1,948,551,368.50, which is a 5.82% increase from the end of the previous year[5] - Total assets reached CNY 1,948,551,368.50 as of March 31, 2022, up from CNY 1,841,426,562.78 at the end of 2021, indicating a growth of 5.8%[14] - Total liabilities increased to CNY 526,057,783.36 from CNY 456,012,175.77, reflecting a rise of 15.3%[14] Cash Flow - Cash flow from operating activities showed a net increase of 134.47% due to higher sales revenue[7] - Cash inflow from operating activities for Q1 2022 was CNY 214,485,323.46, up from CNY 139,927,816.64 in Q1 2021, marking a growth of about 53%[19] - The net cash flow from operating activities for Q1 2022 was CNY 9,037,458.54, a significant improvement from a net outflow of CNY 26,216,473.71 in Q1 2021[19] - Cash inflow from financing activities in Q1 2022 was CNY 115,370,000.00, compared to CNY 61,688,970.93 in Q1 2021, reflecting an increase of approximately 87%[20] - The net cash flow from financing activities for Q1 2022 was CNY 66,972,377.01, up from CNY 53,605,980.77 in Q1 2021, showing an increase of about 25%[20] - The total cash and cash equivalents at the end of Q1 2022 amounted to CNY 133,470,273.95, down from CNY 150,064,013.89 at the end of Q1 2021[20] Investment Activities - The company reported a net cash outflow from investing activities of -118.68%, primarily due to reduced project payments[7] - The cash outflow from investing activities for Q1 2022 was CNY 37,367,093.75, compared to CNY 133,876,080.15 in Q1 2021, showing a decrease of about 72%[20] - The company received CNY 28,581,278.02 from investment activities in Q1 2022, a decrease from CNY 180,910,415.47 in Q1 2021, reflecting a decline of approximately 84%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,417[9] Research and Development - Research and development expenses for Q1 2022 were CNY 10,847,878.76, compared to CNY 9,498,113.15 in Q1 2021, showing a growth of 14.2%[17] Financial Expenses - The company reported a decrease in financial expenses, which were CNY 2,418,434.28 in Q1 2022, down from CNY 929,220.95 in Q1 2021[17] Inventory and Receivables - Inventory as of March 31, 2022, was CNY 161,128,048.87, an increase of 13.1% from CNY 142,442,042.74 at the end of 2021[12] - The accounts receivable financing decreased by 70.38%, attributed to bank acceptance discounts and endorsements[7] - Short-term borrowings rose to CNY 252,329,771.89 from CNY 171,193,229.29, marking a 47.5% increase[13] - The company's short-term borrowings increased by 47.39% during the reporting period[7]

Financial Performance - In 2021, the company achieved a revenue of CNY 1,042,305,915.97, representing a 41.61% increase compared to CNY 736,063,748.91 in 2020[20]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 101,370,204.55, a slight increase of 0.92% from CNY 100,446,704.13 in 2020[20]. - The net profit after deducting non-recurring gains and losses was CNY 98,518,949.74, which is a 12.52% increase from CNY 87,553,103.43 in 2020[20]. - The company's total assets as of the end of 2021 were CNY 1,841,426,562.78, reflecting a 12.53% increase from CNY 1,636,416,118.84 at the end of 2020[21]. - The net assets attributable to shareholders of the listed company increased by 6.39% to CNY 1,382,705,623.96 at the end of 2021, compared to CNY 1,299,661,888.92 at the end of 2020[21]. - The company achieved operating revenue of 1,042.31 million RMB in 2021, representing a year-on-year increase of 41.61%[29]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 98.52 million RMB, up 12.52% compared to the previous year[29]. - The company reported a negative cash flow from operating activities of CNY -11,536,768.28 in 2021, a significant decrease from CNY 93,304,352.91 in 2020, indicating a 112.36% decline[20]. - The weighted average return on equity decreased by 0.30 percentage points to 7.63% in 2021[22]. - The basic earnings per share for 2021 was 0.76 RMB, unchanged from the previous year[22]. Research and Development - Research and development expenses amounted to CNY 41,459,191.08, up 13.32% compared to the previous year, accounting for 3.98% of total revenue[33][44]. - The company has 38 ongoing projects, with 18 newly initiated projects and 9 projects successfully completed during the reporting period[32]. - The company has established a new research center of 8,000 square meters, enhancing its technical development capabilities[32]. - The company is focusing on innovation in synthetic lubricating base oils to meet the growing demand in the automotive and refrigeration industries[40][41]. - The company emphasizes R&D innovation, maintaining a high level of investment to ensure competitive advantage[68]. - The company has established a provincial-level technology center and a provincial-level engineering research center for water-soluble pharmaceutical excipients[83]. - The company has collaborated with well-known domestic universities and research institutions to enhance its R&D capabilities[83]. - The company has initiated several new R&D projects, including the development of a new generation of polyol ester series products with an investment of 1,934,204.48 RMB[87]. Market and Sales Performance - Sales volume of synthetic lubricating base oil increased by 26.72% year-on-year, with sales revenue growing by 55.59%[30]. - The sales volume of pharmaceutical excipients grew by 7.24% year-on-year, with sales revenue increasing by 17.88%[31]. - The company expanded its overseas market presence, particularly in synthetic lubricating base oils, amid rising domestic demand[30]. - The company’s revenue from synthetic lubricating base oil reached CNY 73,707.75 million, with a year-on-year increase of 55.59%[78]. - Domestic sales accounted for CNY 69,551.76 million, reflecting a growth of 35.84% year-on-year[79]. - The company is investing heavily in R&D, allocating 10% of its revenue to develop new products and technologies, focusing on innovative drug formulations[118]. Financial Management and Risks - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[7]. - The company faces challenges from global supply chain issues and extreme weather, impacting production and operations[29]. - The company faces risks from external factors such as rising raw material prices and inflationary pressures, which may impact profit margins[106]. - The company relies heavily on ethylene oxide and propylene oxide as key raw materials, and any supply disruptions or price volatility could directly impact production and financial performance[109]. - Environmental regulations are becoming stricter, and increased compliance costs could affect the company's operational performance if higher environmental standards are imposed[110]. Corporate Governance and Management - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of its financial statements[8]. - The company has a structured salary management system that includes fixed and performance-based compensation, aimed at motivating employees and ensuring sustainable development[135]. - The company emphasizes talent development through annual training plans, combining internal and external training to enhance employee skills and management capabilities[136]. - The company has a comprehensive remuneration structure for senior management, including a base salary and performance-based incentives[122]. - The company has established a joint venture, Nanjing Xingwei Biotechnology Co., Ltd., with a registered capital of RMB 50 million, where the company contributed RMB 25.5 million, accounting for 51%[193]. Shareholder and Equity Management - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares, totaling CNY 40,643,529.60, subject to approval at the annual general meeting[5]. - The total number of shares held by the company's directors and senior management at the end of the reporting period was 64,087,939, a decrease of 1,029,000 shares compared to the beginning of the year[116]. - The company has committed to a 36-month lock-up period for major shareholders following the IPO, with automatic extensions under certain conditions[158]. - The company will use at least 20% of the previous year's audited net profit for share repurchase actions aimed at stabilizing the stock price[172]. - The company will ensure compliance with relevant laws and regulations regarding share repurchase and stock price stabilization measures[172]. Environmental and Social Responsibility - The environmental protection subsidiary, Weir Bio-Tech, did not exceed pollutant discharge limits during the reporting period[148]. - The company has established an emergency response plan for environmental incidents, which was revised in September 2021 and filed with the local emergency management bureau[152]. - The company has passed the ISO14001 environmental management system certification, ensuring compliance with local environmental standards[154]. - There were no administrative penalties due to environmental issues during the reporting period[155].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 南京威尔药业集团股份有限公司 2021 年第三季度报告 证券代码：603351 证券简称：威尔药业 南京威尔药业集团股份有限公司 2021 年第三季度报告 | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益（包括已 | -63,071.43 | -181,511.59 | | | 计提资产减值准备的冲销部分） | | | | | 计入当期损益的政府补助（与公 | | | | | 司正常经营业务密切相关，符合 | | | | | 国家政策规定、按照一定标准定 | 500,0 ...

南京威尔药业集团股份有限公司 2021 年半年度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2021 年半年度报告 二〇二一年七月 中国 南京 1 / 125 南京威尔药业集团股份有限公司 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人吴仁荣、主管会计工作负责人唐群松及会计机构负责人（会计主管人员）杨轶声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确 ...

中国 南京 南京威尔药业集团股份有限公司 2021 年第一季度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2021 年第一季度报告 二〇二一年四月 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 末增减(%) | | | --- | --- | --- | --- | --- | | 总资产 | 1,692,772,461.39 | 1,636,416,118.84 | | 3.44 | | 归属于上市公司股东 | 1,326,308,127.61 | 1,299,661,888.92 | | 2.05 | | 的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的现金 | -26,216,473.71 | 20,698,657.55 | | -226.66 | | 流量净额 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减（%） | | | 营业收入 | 227,430,578.90 | 155,40 ...

Financial Performance - In 2020, the company's operating revenue was CNY 736,063,748.91, a decrease of 16.43% compared to CNY 880,756,050.50 in 2019[21] - The net profit attributable to shareholders was CNY 100,446,704.13, down 21.59% from CNY 128,107,850.57 in the previous year[21] - The net cash flow from operating activities was CNY 93,304,352.91, a decline of 28.06% from CNY 129,694,099.65 in 2019[22] - Basic earnings per share decreased to CNY 0.77, down 23.00% from CNY 1.00 in 2019[23] - The weighted average return on equity was 7.93%, a decrease of 3.22 percentage points from 11.15% in 2019[23] - The company achieved total operating revenue of 736,063,748.91 yuan in 2020, a decrease of 16.43% compared to the previous year[43] - The net profit attributable to shareholders was 10,044.67 million yuan, down 21.59% year-on-year[43] - Total operating revenue decreased by 16.84% to CNY 729,592,107.30, with a gross profit margin of 34.33%[49] - The revenue from base oil was CNY 473,737,564.80, down 23.11% year-on-year, with a gross margin of 19.45%[48] - The revenue from pharmaceutical excipients was CNY 225,351,513.06, with a gross margin of 65.33%, showing a slight decrease of 2.70%[48] Sales and Market Impact - The company faced a decline in sales volume and revenue due to the impact of the pandemic[23] - Sales volume of synthetic lubricating base oil decreased by 13.15%, and sales revenue dropped by 23.11% due to the impact of the pandemic on key manufacturers[36] - The sales volume of pharmaceutical excipients decreased by 1.70%, with sales revenue declining by 2.70% during the reporting period[37] - Domestic sales revenue was CNY 44,621.55 million, down 23.63% year-on-year, while international sales revenue was CNY 2,752.22 million, down 13.55%[98] Research and Development - The company invested 36,586,783.85 yuan in R&D, accounting for 4.97% of operating revenue, reflecting a commitment to innovation[40] - The company established a research institute with over 100 professionals to enhance its R&D capabilities[40] - The company emphasizes independent research and development, with a focus on injectable pharmaceutical excipients, and has established partnerships with universities and research institutions[66] - The company has created provincial-level technology centers to enhance its R&D capabilities and foster collaboration with domestic pharmaceutical enterprises[66] - The company's R&D investment accounted for 4.97% of operating revenue during the reporting period[71] - The company reported a significant increase in R&D investment for the "Fatty Acid Polyether Ester Series Product" by 267.87% compared to the previous year[73] Operational Adjustments - The company has adjusted its organizational structure to enhance its marketing capabilities, establishing a dedicated marketing company for product sales and customer development[31] - The company has established a complete procurement management system to ensure quality and compliance in its purchasing processes[31] - The company has developed a complete procurement management system, including qualified supplier management and procurement process management[82] - The company has established a sales system that primarily focuses on direct sales to pharmaceutical and large lubricating oil manufacturers[82] Future Outlook and Strategy - The company aims to enhance its competitive edge in the pharmaceutical excipients industry through increased R&D investment and the development of new product categories[34] - The company aims to become a leading enterprise in the pharmaceutical excipients and synthetic lubricating base oil industry through technological innovation and excellent operations over the next 3-5 years[105] - The company plans to invest CNY 100 million in a venture capital partnership, holding a 10% stake, with an initial contribution of CNY 40 million[99] - The company intends to improve its capital operation capabilities, focusing on investment and mergers to accelerate business expansion and promote research innovation[111] Environmental Compliance - The company has implemented online monitoring equipment for pollutant discharge, ensuring compliance with environmental regulations[169] - During the reporting period, the company did not exceed the approved pollutant discharge limits, maintaining all emissions within regulatory standards[164] - The company has established emergency response plans for environmental incidents, which have been filed with local environmental authorities[168] - The company has completed environmental impact assessments for all construction projects, receiving approval from local environmental departments[167] - The company’s wastewater treatment capacity is 250 tons per day, with all systems reported to be operating normally[166] Shareholder and Management Information - The company has a commitment to maintain a safety production system during the expansion of its production scale to mitigate risks associated with hazardous materials[115] - The company’s board of directors was re-elected on April 8, 2020, for a term of three years[192] - The company’s total pre-tax remuneration for directors and senior management amounted to 500.31 million yuan for the reporting period[191] - The company does not have a controlling shareholder or actual controller, ensuring independent management[188] Financial Management and Investments - The company has engaged in various financial products, including a RMB 10 million investment with a floating return of 3.40%, yielding RMB 56.82 thousand[161] - The company has also invested RMB 7.2 million in a financial product with a return of 3.35%, generating RMB 20.10 thousand in income[161] - The company has a significant investment of RMB 15.4 million with a return of 2.95%, resulting in an income of RMB 119.4 thousand[162] - The company is actively managing its idle funds to ensure liquidity and safety while seeking returns through various financial products[160] Risks and Challenges - The company faces risks related to product and technology development, including potential failures in R&D and challenges in achieving market acceptance[113] - The company is exposed to risks from fluctuations in the supply and prices of key raw materials, such as ethylene oxide and propylene oxide, which are closely tied to oil prices[114] - Environmental regulations are tightening, and the company may face increased operational costs to comply with higher environmental protection standards[114]

南京威尔药业集团股份有限公司 2020 年第三季度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2020 年第三季度报告 二〇二〇年十月 中国 南京 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 南京威尔药业集团股份有限公司 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | | | | | 单位：元 币种：人民币 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 主要财务数据 | 本报告期末 | | 上年度末 | | 本报告期末比上年度 | | | | | | | | | 末增减(%) | | | | 总资产 | 1,553,848,692.81 | | 1,458,270,541.59 | | 6.55 | | | | 归属于上市公司股东 的净资产 | 1,275,168,763.69 | | 1,241,215,205.79 | | 2.74 ...